NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Surges 31% In Last Quarter
Arcutis Biotherapeutics (ARQT) recently announced the submission of a supplemental New Drug Application for ZORYVE® cream, aiming to treat plaque psoriasis in young children, which aligns with the company's ongoing innovation efforts. Over the last quarter, ARQT's price moved 31%, a significant contrast to the broader market's steady uptrend. While market optimism has been buoyed by tech gains and reduced inflation pressures, Arcutis's substantial price movement was likely driven by its...